NeurogesX Shares Jump With FDA Approval
Finance World News Update by EQUITIES Magazine
Beverly Hills 11/17/2009 06:44 PM GMT (TransWorldNews)
Stocks of NeurogesX Inc. rose 51 cents, or 6.2 percent, to $8.75 after the biotechnology company received FDA approval for its Qutenza pain patch. The company plans to launch the drug in the first half of 2010 in the U.S.
The FDA approved Qutenza as a treatment for postherpetic neuralgia, a type of nerve pain condition that results from shingles.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
info@equitiesmagazine.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
EQUITIES Magazine
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
